<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551382</url>
  </required_header>
  <id_info>
    <org_study_id>142/06</org_study_id>
    <secondary_id>20060504(142/06)</secondary_id>
    <nct_id>NCT00551382</nct_id>
  </id_info>
  <brief_title>Montelukast as Prophylaxis for Upper Respiratory Tract Infections in Children: a Randomised, Double-blind, Placebo-controlled Study</brief_title>
  <official_title>Phase 3 Study of Montelukast as Prophylaxis for Upper Respiratory Tract Infections in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Viral upper respiratory tract infection (URI) is one of the most common diseases among
      toddlers and pre-school children.Complete and effective prevention measures for URI are
      currently unavailable.

      Montelukast (Singulair ) is a selective leukotriene-receptor antagonist that inhibits the
      cysteinyl leukotriene 1 receptor. It is well tolerated and safe even in young children.
      Montelukast is an effective treatment for asthma (and allergic rhinitis from 1 year of age.
      Infections with viruses causing URI such as Influenza A, Rhinovirus and respiratory syncitial
      virus increases leukotriens levels in nasal secretions. Therefore, one may postulate that
      leukotriens inhibitors may reduce symptoms during URI. However the effect of montelukast as a
      treatment for non-specific cough was not properly studied and there are no studies on the
      effect of montelukast as prevention for URI.

      Hypothesis: Prophylactic treatment with Montelukast will reduce the incidence and severity of
      upper respiratory infection in children.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number and duration of URI episodes</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of URI episodes,number of days with fever,antibiotic and antipyretic usage, unscheduled visits to physicians office, child's absence from day care or kindergarten, parental absence from work, hospital admissions and adverse reaction of the drug.</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Upper Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Muntelukast</intervention_name>
    <description>Tablets or granules; 4 mg once a day for 12 weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Singulair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Look alike tablets or granules 1 per day for 12 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 1 to 5 years old without significant health problem.

        Exclusion Criteria:

          -  A previous history of wheezing (requiring treatment with bronchodilators in the last 3
             month or more than one treatment in the last year)

          -  Hospital admission due to reactive air way disease

          -  Prophylactic use of montelukast or steroids

          -  Chronic cardiac or respiratory disease

          -  Presence of acute respiratory tract infection within the 7 days before consideration
             for the study

          -  History of allergic Rhinitis

          -  Children who are receiving chronic medications of any kind

          -  Known allergy to montelukast

          -  Inability to get an informed consent from a legal guardian.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mati Berkovitch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eran Kozer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mati Berkovitch, MD</last_name>
    <phone>972 8 9779152</phone>
    <email>mberkovitch@asaf.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eran Kozer, MD</last_name>
    <phone>972 8 9778131</phone>
    <email>erank@asaf.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kupat Cholim Clalit</name>
      <address>
        <city>Lod</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Al Garushi</last_name>
    </contact>
    <investigator>
      <last_name>Al Garushi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kupat Cholim Clalit</name>
      <address>
        <city>Ramla</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zachi Lotem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berkovitch</last_name>
      <phone>97289779152</phone>
    </contact>
    <investigator>
      <last_name>Mati Berkovitch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2007</study_first_submitted>
  <study_first_submitted_qc>October 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2007</study_first_posted>
  <last_update_submitted>March 16, 2010</last_update_submitted>
  <last_update_submitted_qc>March 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Berkovitch M</name_title>
    <organization>Assaf Harofeh Medical Center</organization>
  </responsible_party>
  <keyword>Montelukast</keyword>
  <keyword>Upper respiratory tract infection</keyword>
  <keyword>leukotriene</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

